Claudia Grimaldi
Known title: PFOCIK: 0001745853
Associated companies
Transaction History
| IGC | ▼ Sell | Gift | 150,000 | $0 | 9/25/2026 | View on chart |
| IGC | ▲ Buy | Grant | 2,048,378 | $553K | 6/30/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 4/1/2026 | View on chart |
| IGC | ▲ Buy | Option Exercise | 138,462 | $36K | 4/1/2026 | View on chart |
| IGC | ▼ Sell | Gift | 50,000 | $0 | 10/17/2025 | View on chart |
| IGC | ▲ Buy | Option Exercise | 83,333 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 58,333 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 100,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 95,000 | $0 | 3/13/2024 | View on chart |
| IGC | ▲ Buy | Option Exercise | 83,333 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 58,334 | $0 | 3/31/2023 | View on chart |
| IGC | ▲ Buy | Option Exercise | 9,375 | $0 | 6/1/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 28,125 | $0 | 5/31/2022 | View on chart |
| IGC | ▲ Buy | Option Exercise | 83,334 | $0 | 3/21/2022 | View on chart |
| IGC | ▲ Buy | Grant | 250,000 | $0 | 12/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused
IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.
IGC Pharma Enters Phase 2 Alzheimer's Trial; DEA Hearing Paused. IGC Pharma has joined a Phase 2 study for its CALMA drug in Alzheimer’s disease, with results due in Q4 2026. Separately, a U.S. DEA judge paused a hearing on marijuana rescheduling after opponents cited a government report that highlighted gaps in federal procedures. The pause may affect the regulatory environment for cannabis‑derived products, while the trial marks a new development for IGC’s pipeline.